The receptor-type protein tyrosine phosphatase epsilon (RPTPe) activates c-Src in mammary tumor cells induced in vivo by Neu. Tumor cells lacking RPTPe exhibit reduced c-Src activity, appear less transformed morphologically and proliferate slower in vitro and in vivo. Expression of Src rescues most of these phenotypes, indicating that c-Src activity is important for maintaining the transformed phenotype. However, the molecular mechanisms that control activation of c-Src by RPTPe are unknown. We show that Neu induces phosphorylation of RPTPe exclusively at its C-terminal Y695, and that this phosphorylation is required for activation of c-Src by RPTPe. Phosphorylation of RPTPe does not affect its activity toward another substrate, the voltage-gated potassium channel Kv2.1, suggesting that phosphorylation directs RPTPe activity toward c-Src. Phosphorylation of RPTPe reduces its dimerization at the cell membrane, although this does not affect its activity significantly. RPTPe is subject to strong auto-and trans-dephosphorylation, suggesting that dephosphorylation limits the activation of c-Src downstream of Neu. We conclude that an Neu-RPTPe-Src signaling pathway exists in mammary tumor cells, in which phosphorylation of RPTPe by Neu directs RPTPe to activate c-Src. Reversible phosphorylation of RPTPe at Y695 may thus function as a 'molecular switch', which affects the substrate specificity of the phosphatase.
Introduction
Activity of c-Src is influenced heavily by tyrosine phosphorylation. Phosphorylation of the conserved C-terminal tyrosine residue of c-Src (Y527 in the prototypic chicken enzyme) by C-terminal Src kinase and the related homologous kinase (CHK) kinases allows this residue to bind the SH2 domain of the same c-Src molecule, thereby inactivating the kinase (Mustelin and Hunter, 2002; Cole et al., 2003; Boggon and Eck, 2004; Chong et al., 2005) . In agreement, dephosphorylation of the C-terminal tyrosine by tyrosine phosphatases (PTPs) activates c-Src. PTPs known to perform this role include PTP1B, SHP1, SHP2, DEP-1, CD45, RPTPa, PTPe and PTPRO (Mustelin and Hunter, 2002; Gil-Henn and Elson, 2003; Pera et al., 2005; Roskoski, 2005; Lau et al., 2006) . Of these, the molecular details concerning RPTPa are the most complete.
RPTPa has been suggested to activate c-Src by a competitive displacement mechanism, in which the phosphorylated C-terminal tyrosine (pY789) of RPTPa competes against phospho-Y527 of c-Src for binding the Src SH2 domain (Zheng et al., 1992 (Zheng et al., , 2000 . This process exposes pY527 and enables its dephosphorylation by the catalytic domain of RPTPa. In agreement with this model, Y789F RPTPa, which cannot be phosphorylated at position 789, cannot activate c-Src. Furthermore, phosphorylation at the juxtamembrane sites S180 and S204, in conjunction with phosphorylation at Y789, helps direct RPTPa activity toward c-Src (Tracy et al., 1995; Zheng et al., 2000 Zheng et al., , 2002 Zheng and Shalloway, 2001 ). Activation of c-Src by RPTPa affects diverse physiological phenomena that include cell transformation, regulation of integrin signaling and neuronal differentiation and outgrowth (den Hertog et al., 1993; Harder et al., 1998; Ponniah et al., 1999; Su et al., 1999; Zheng et al., 2002; Pallen, 2003; von Wichert et al., 2003; Zeng et al., 2003; Bodrikov et al., 2005; Maksumova et al., 2005) .
RPTPe and RPTPa are the only members of the type IV subfamily of receptor-type PTPs. The two major forms of PTPe protein are the receptor-type form (RPTPe) and the nonreceptor form (cyt-PTPe), which are produced by distinct promoters of the Ptpre gene (Elson and Leder, 1995a, b) . Additional products of the Ptpre gene are the p67 PTPe and p65 PTPe proteins, whose production is regulated at the levels of transcription and post-translational processing, respectively . The role of RPTPe as a direct activator of c-Src was demonstrated in mouse mammary tumors induced in vivo by activated Neu, and which express high levels of RPTPe (Elson and Leder, 1995b; Gil-Henn and Elson, 2003) . Among other data, activities of c-Src, c-Yes and c-Fyn were reduced in mammary tumors induced by Neu in mice genetically lacking PTPe (EKO mice). In agreement, c-Src formed a stable complex with the D302A 'substrate-trapping' mutant of RPTPe, strongly suggesting that this kinase is a direct substrate of RPTPe (Gil-Henn and Elson, 2003; GranotAttas and Elson, 2004) . Furthermore, mammary tumor cells from EKO mice appeared morphologically less transformed and proliferated slower in culture and upon implantation in nude mice. The morphology of these cells was corrected upon expression of active c-Src, indicating that at least this aspect of the EKO phenotype was caused by reduced c-Src activity secondary to lack of RPTPe (Gil-Henn and Elson, 2003) . Interestingly, lack of RPTPe in these tumor cells affected Src family kinases (SFKs) and resulted in cellular phenotypes despite significant expression of RPTPa. This may suggest that subtle differences exist between the roles of these two related PTPs, or that a full complement of Src-dephosphorylating PTPs is required for appropriate activation of Src.
c-Src is a well-established collaborator of Neu in transformation of mouse mammary epithelial cells in vivo (Guy et al., 1994; Luttrell et al., 1994; Muthuswamy et al., 1994; Muthuswamy and Muller, 1995a, b; Belsches-Jablonski et al., 2001; Kim et al., 2005) . Although RPTPe plays a significant role in activating c-Src downstream of Neu in this system, the mechanisms that regulate RPTPe activity toward c-Src are not known. We demonstrate here that a Neu-RPTPe-Src signaling pathway exists in mammary tumor cells, in which Neu-mediated phosphorylation of RPTPe drives the latter to activate c-Src. The data also suggest that phosphorylation of RPTPe at Y695 may act as a molecular 'switch' that helps determine the substrate specificity of this phosphatase.
Results
RPTPe is phosphorylated at Y695 in Neu-induced mammary tumor cells In order to characterize the molecular mechanisms that regulate activation of Src by RPTPe in Neu-induced mammary tumor cells, we examined whether RPTPe is phosphorylated on tyrosine residues in these cells. Indeed, endogenous RPTPe was precipitated from lysates of Neu-induced mammary tumor cells with antiphosphotyrosine antibodies (Figure 1a) . No RPTPe was detected in the absence of precipitating antibody nor in precipitates from Neu-induced mammary tumor cells of EKO mice that genetically lack RPTPe. RPTPe is a glycoprotein, and fully-glycosylated and nonglycosylated forms of RPTPe are usually detected in cells (Elson and Leder, 1995b) . Only fully glycosylated RPTPe was phosphorylated in these studies, suggesting that phosphorylation occurs or is maintained mainly at the cell membrane ( Figure 1a) . Previous studies have shown that Y695 of RPTPe, located at the C terminus of this PTP, can be phosphorylated (Toledano-Katchalski and Elson, 1999) . Protein-blotting studies using an antibody specific for pY695 RPTPe indicated that Figure 1b and data not shown). Finally, WT RPTPe, but not its Y695F mutant, was phosphorylated upon expression in Neu-induced tumor cells from EKO mice (Figure 1c ), confirming phosphorylation of RPTPe exclusively at Y695 in this system. The above results were recapitulated in 293 cells. RPTPe is poorly phosphorylated in these cells; phosphorylation was increased significantly following the coexpression of activated Neu (V664E Neu, referred to here as NeuNT), the allele of Neu that induced mammary tumors in transgenic mice used in this study (Muller et al., 1988; Figure 2a) . As in mammary tumor cells, phosphorylation was detected mainly in fully glycosylated RPTPe, in agreement with strong colocalization of RPTPe and NeuNT at the cell membrane ( Figure 2c ). Y695F RPTPe was phosphorylated at background levels in these cells, confirming that Neu induces phosphorylation of RPTPe at Y695 in this system. Similar results were obtained when phosphorylation of RPTPe in 293 cells was examined with the anti-pY695 RPTPe antibody (Supplementary Figure 1) . Y695 in RPTPe is identical to Y638 in cyt-PTPe; this site was phosphorylated when cyt-PTPe was coexpressed with NeuNT ( Figure 2b ). Phosphorylation of RPTPe and of cyt-PTPe by Neu is then highly specific and occurs at a single tyrosine residue of the 22 tyrosines found in either form of PTPe. Similar results were observed also in NIH3T3 and SYF cells, indicating that this phosphorylation is not cell typespecific.
Phosphorylation of RPTPe in 293 cells is dependent on the strength of the Neu kinase used, as NeuN, a nonactivated allele of Neu, induced weaker phosphorylation of RPTPe and of cyt-PTPe (Figure 3a and b) . Further studies indicated that membranal localization promotes PTPe phosphorylation by Neu. Although cyt-PTPe is predominantly cytosolic, a fraction of cyt-PTPe molecules is found at the cell membrane (Elson and Leder, 1995a) . In contrast, p67 PTPe, which lacks the 27 Nterminal residues of cyt-PTPe and is entirely cytosolic , was phosphorylated very weakly in the presence of NeuNT and not at all in the presence of NeuN (Figure 3b ). The residues missing from p67 PTPe lack tyrosines, hence reduced phosphorylation of this molecule is not due to removal of phosphorylation sites. Phosphorylation of RPTPe downstream of Neu is not simply the result of expression of an active kinase in a heterologous system, since the expression of activated Dephosphorylation of the C-terminal tyrosine of PTPe Phosphorylated PTPe was detected only when cell lysis and immunoprecipitation were performed in the presence of the PTP-inhibitor sodium pervanadate, indicating that PTPe is subject to dephosphorylation. In contrast, phosphorylation of the substrate-trapping mutants, D302A RPTPe and D245A cyt-PTPe, was significantly stronger and was detected also in the absence of sodium pervanadate (Figure 4a and b). Dto-A type substrate-trapping mutants of PTPs are virtually inactive, but bind their substrates and can protect them from dephosphorylation by active PTP molecules (Flint et al., 1997) . Although this result indicates that PTPe is a substrate of itself, increased phosphorylation of the D-to-A mutants in the presence of pervanadate (Figure 4 ) suggests that other PTPs may dephosphorylate PTPe as well.
Phosphorylation of RPTPe at Y695 is essential for activation of c-Src Y695 of RPTPe is analogous to Y789 in RPTPa, which participates in activating c-Src (Zheng et al., 2000) . In order to determine whether phosphorylation of RPTPe at Y695 affects c-Src activation, we expressed WT or Neu activates c-Src via RPTPe phosphorylation D Berman-Golan and A Elson that the expression of RPTPe does not cause widespread changes in cellular protein phosphorylation (not shown). Phosphorylation of the related RPTPa on serines 180 and 204 in its cytosolic juxtamembrane region can help direct RPTPa activity toward c-Src by inhibiting binding of Grb2 to phosphorylated Y789 at the C terminus of the phosphatase (Tracy et al., 1995; Zheng et al., 2002) . S180 is replaced in RPTPe by an aspartic acid, which may mimic constitutive phosphorylation at this site. S204 is conserved in RPTPe, but its replacement with an aspartic acid did not cause reproducible changes in RPTPe activity toward c-Src (not shown). It is, therefore, possible that RPTPe is less sensitive than RPTPa to regulation by phosphorylation on its juxtamembrane serine residue, although this issue requires further study. 
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In order to examine this issue, we expressed RPTPe tagged with either hemagglutinin (HA) or FLAG in 293 cells, either in the presence or absence of NeuNT. Following the immune precipitation of FLAG-tagged molecules, presence of dimerized, coprecipitating HAtagged molecules was determined by blotting the precipitate with anti-HA antibodies. In agreement with previous studies (Toledano-Katchalski et al., 2003) , RPTPe dimers were detected readily among both nonglycosylated and fully-glycosylated RPTPe molecules (Figure 6a ). Expression of NeuNT significantly reduced dimerization of the fully glycosylated, membrane-associated RPTPe molecules without affecting the nonglycosylated molecules ( Figure 6a ). As Neumediated phosphorylation of RPTPe at Y695 is also limited to the glycosylated form of RPTPe (Figures 1-4) , this result suggests that phosphorylation of RPTPe at Y695 may reduce dimerization of RPTPe. Interestingly, no reduction in dimerization was noted when cyt-PTPe was examined in the same system (not shown). The reasons for this are not clear at present and require further study.
In order to examine whether these changes in dimerization increase RPTPe activity in vivo, we studied dephosphorylation of the voltage-gated potassium channel Kv2.1 by RPTPe in intact cells. A similar system was used previously to show that increased dimerization of cyt-PTPe reduces its ability to dephosphorylate Kv2.1 in cells (Toledano-Katchalski et al., 2003) . cyt-PTPe dephosphorylates Kv2.1 predominantly at Y124, thereby down-regulating channel activity and countering phosphorylation of this residue by c-Src. RPTPe can dephosphorylate Kv2.1 as well (Peretz et al., 2000; Tiran et al., 2003) . We, therefore, expressed Kv2.1 in the presence of Y527F Src, which cannot be activated by RPTPe, to ensure channel phosphorylation. RPTPe was expressed in the cells, either in the presence or absence of Neu, and phosphorylation of Kv2.1 was evaluated (Figure 6b ). Kv2.1 was tyrosine-phosphorylated strongly when expressed together with activated Src, but very weakly when expressed with NeuNT ( Figure 6b, lanes 3 and 4) . Coexpressing NeuNT with Y527F Src did not increase the phosphorylation of Kv2.1 beyond levels observed with Src alone, indicating that the direct effect of NeuNT on Kv2.1 phosphorylation was minimal (lane 5). In agreement with previous studies, expression of RPTPe nearly eliminated Kv2.1 phosphorylation (lane 6). Expression of reduced amounts of WT or Y695F RPTPe resulted in intermediate and similar levels of phospho-Kv2.1, indicating that phosphorylation of Kv2.1 responds to changes in RPTPe activity in this system, and that phosphorylation of RPTPe at Y695 does not affect its activity toward Kv2.1 significantly (Figure 6b, lanes 7 and 8) .
Examination of the catalytic activity of purified, phosphorylated RPTPe in vitro proved extremely difficult. RPTPe autodephosphorylation (Figure 4 ) required the use of PTP inhibitors to preserve phosphorylation of RPTPe during its isolation, thus precluding subsequent PTP activity assays. Similar difficulties prevented the use of RPTPe phosphorylated by Neu in vitro. In order to resolve this issue, at least in part, we replaced Y695 with a glutamic acid residue, a modification often used to mimic phosphorylation of proteins, including on tyrosine residues (Meyer et al., 2002; Guo et al., 2004 Furthermore, only glycosylated, membrane-associated RPTPe is phosphorylated by Neu; since phosphorylation is required for its activation of c-Src, the data suggest that only the mature membrane-associated form of RPTPe targets c-Src. Neu-mediated phosphorylation of RPTPe and cyt-PTPe with the same characteristics was detected in several cell types, including Neu-induced mammary tumor cells, indicating that it is a general phenomenon and is not cell type specific. Although we believe phosphorylation of PTPe by Neu is direct, this issue requires further study. Phosphorylated RPTPe and cyt-PTPe are subject to strong dephosphorylation. In comparison, phosphorylation of the substrate-trapping mutants D302A RPTPe and D245A cyt-PTPe is detected readily. This last result is due either to the significantly reduced activity of D-to-A mutants or to their ability to bind their phosphotyrosine substrates and protect them from dephosphorylation by active PTP molecules (Flint et al., 1997) . Both explanations are consistent with RPTPe and cyt-PTPe undergoing autodephosphorylation, although they do not distinguish between inter-and intra-molecular events. Importantly, increased phosphorylation of the virtually inactive D-to-A PTPe mutants in the presence of the PTP inhibitor pervanadate suggests that other PTPs also dephosphorylate PTPe. PTPe is, therefore, most likely a substrate of itself as well as of other PTPs.
Phosphorylation of RPTPe by Neu drives the phosphatase to activate c-Src, raising the question of whether this affects other substrates of RPTPe as well. A general increase in RPTPe activity would predict significant increases -on the order of 120% as measured toward c-Src ( Figure 5 ) -in RPTPe activity toward other substrates. In agreement with the Src-specific phospho-displacement model, we did not observe the increased activity of phosphorylated RPTPe toward Kv2.1 in intact cells, despite the ability of the system used to detect increased RPTPe activity of the expected magnitude. Additional support for lack of a general increase in RPTPe specific activity was evident in the absence of increased activity of Y695E RPTPe toward the general phosphatase substrate PNPP. However, interpretation of this latter experiment is more limited since the Y-to-E mutation cannot mimic all properties of phosphotyrosine, such as binding SH2 domains.
Dimerization inhibits PTPe activity (Toledano-Katchalski et al., 2003), hence it is somewhat surprising that reduced dimerization did not increase RPTPe activity toward Kv2.1 (Figure 6b ). Since 12-25% of PTPe molecules are dimerized (Toledano-Katchalski et al., 2003) and since phosphorylation reduces but does not eliminate RPTPe dimerization (Figure 6a ), phosphorylation may increase the fraction of monomeric RPTPe molecules by a relatively small extent that is below the sensitivity of the in vivo method used here (Figure 6b ). In all, our results are broadly consistent with phosphorylated RPTPe activating c-Src mainly via the phosphotyrosine displacement mechanism, that is, by RPTPe specifically targeting c-Src and related molecules. We cannot, however, rule out entirely the possibility that Neu-mediated phosphorylation also increases somewhat the specific activity of RPTPe in a manner that is not substrate specific.
This study identifies Neu as an upstream kinase, whose phosphorylation of RPTPe directs the latter to activate c-Src (Figure 7 ). c-Src is a well-established collaborator of Neu in transformation of mammary epithelial cells and is activated in tumors induced by Neu. c-Src binds Neu in mammary tumor cells and participates in mediating molecular events further downstream (Luttrell et al., 1994; Muthuswamy et al., 1994; Muthuswamy and Muller, 1995b; BelschesJablonski et al., 2001; Kim et al., 2005) . The central role of RPTPe in the Neu-RPTPe-Src signaling system is consistent with high expression of RPTPe in mouse mammary tumors initiated in vivo by Neu (Elson and Leder, 1995b) and with reduced c-Src activity and altered properties of tumor cells from mice lacking RPTPe (Gil-Henn and Elson, 2003) . Neu is constitutively active in this mammary tumor system, hence RPTPe phosphorylation is expected to reflect a balance between constant phosphorylation and dephosphorylation activities. However, it is tempting to speculate that regulation of RPTPe is more dynamic in systems where kinase activity can be induced. In such cases, kinase activation could induce phosphorylation of the C-terminal tyrosine of PTPe, which would then activate c-Src. Once kinase activity is downregulated, dephosphorylation of PTPe would direct PTPe activity away from c-Src. Taken more to an extreme, phosphorylation of RPTPe at Y695 could determine the nature of its activity toward substrates that are not SFKs (Figure 7) . Nonphosphorylated RPTPe could directly dephosphorylate the non-SFK substrates, while pY695 RPTPe could indirectly phosphorylate the same or other substrates by activating c-Src (Figure 7 ). Further studies of systems, where activity of ErbB family members can be induced by ligands, are required to analyse the dynamic aspects of this model.

Materials and methods
Reagents
The following cDNAs cloned in pCDNA3 (Invitrogen, Carlsbad, CA, USA) were used in this study: mouse RPTPe, cyt-PTPe, Y695F RPTPe, Y638F and cyt-PTPe (ToledanoKatchalski and Elson, 1999) , D302A RPTPe (Gil-Henn and , D245A cyt-PTPe (Peretz et al., 2000) , p67-PTPe , chicken Y527F c-Src (gift from Dr S Courtneidge), wild-type c-Src (gift from Dr J den Hertog), GFP-Src (gift from Dr J Woodward), rat Kv2.1 (gift from Dr M Lazdunski) and rat NeuN and NeuNT cDNAs (gifts from Dr WJ Muller). Y695E RPTPe was constructed by PCRmediated site-directed mutagenesis followed by sequencing. All PTPe constructs contained FLAG or HA tags at their C terminus. For retroviral infections, mouse WT and Y695F RPTPe FLAG cDNAs were cloned into the pBABE vector (Gil-Henn and Elson, 2003) . Primary antibodies used included polyclonal anti-PTPe (Elson and Leder, 1995b) (Chen and Okayama, 1988) ; SYF cells were transfected with the FuGENE 6 reagent (Roche, Basel, Switzerland). FLAGtagged RPTPe cDNAs were expressed in EKO MMTV-Neu cells by infection with pBABE-based retroviral vectors followed by repeated infection after 2 days. Infected cells were selected in 2 mg/ml puromycin, which was increased gradually to 6 mg/ml.
Immunofluorescence SYF cells were plated on glass cover slips, transfected with the relevant expression vectors and stained with antibodies as described previously . Primary antibodies used were monoclonal anti-HA 11 (Covance, Princeton, NJ, USA) and polyclonal anti-Neu, each diluted 1:450. Secondary antibodies included CY3-conjugated anti-mouse and CY5-conjugated anti-rabbit (1:750 dilution; Jackson Immunoresearch Laboratories, West Grove, PA, USA). Confocal images were collected on a Bio-Rad Laboratories (Hercules, CA, USA) Radiance 2100 Laser Scanning system.
Production of anti-pY695 PTPe antibodies
Rabbit polyclonal antibodies were raised against a peptide containing residues 686-699 of RPTPe; the peptide (QDFI-DIFSD(pY)ANFK) was phosphorylated at Y695 and was coupled via an added N-terminal cysteine to keyhole limpet hemocyanin. Crude serum was purified sequentially on columns containing nonphosphorylated and phosphorylated versions of the above peptide. When used to probe protein blots prepared from crude cell lysates, the antibody detected full-length glycosylated RPTPe phosphorylated by Neu; it did not recognize Y695F RPTPe or nonphosphorylated WT RPTPe (Supplementary Figure 1 and Figure 1b) . Although this antibody can detect cyt-PTPe phosphorylated at Y638 (which is identical to Y695 in RPTPe), we refer to it here as anti-pY695 RPTPe for clarity. Figure 7 Phosphorylation of RPTPe at Y695 as a binary molecular switch: A hypothetical substrate of RPTPe can be dephosphorylated directly by the phosphatase. Alternatively, phosphorylated RPTPe may dephosphorylate and activate c-Src, which can then phosphorylate the same (or a different) substrate. Phosphorylation of RPTPe at Y695, which is regulated physiologically, then determines the choice of substrates of the phosphatase, as well as whether RPTPe will directly dephosphorylate or indirectly phosphorylate substrate molecules.
Neu activates c-Src via RPTPe phosphorylation D Berman-Golan and A Elson
Immunoprecipitation, protein blotting and Src activity assays Cells were washed with phosphate-buffered saline and lysed in cold Buffer A (50 mM Tris-HCl (pH 7.5), 150 mM NaCl and 1% Nonidet P-40 or Igepal), supplemented with protease inhibitors (1 mM N-(a-aminoethyl) benzene-sulfonyl fluoride, 40 mM bestatin, 15 mM E64, 20 mM leupeptin, 15 mM pepstatin; Sigma) and 0.5 mM sodium pervanadate. In some cases, 0.15 mM sodium pervanadate was added to the growth medium 8 min before lysis. For immunoprecipitation via the FLAG tag, 1-2.5 mg of total cell protein were mixed with anti-FLAG M2 affinity beads (Sigma) for 2 h at 41C, followed by three extensive washes with Buffer A or radioimmunoprecipitation assay (RIPA) buffer (150 mM NaCl, 0.5% sodium deoxycholate (DOC), 0.1% sodium dodecyl sulfate (SDS), 50 mM Tris (pH 8) and 1% NP-40 or Igepal). Immunoprecipitation of phosphorylated proteins was performed by incubation of 2-2.5 mg of protein extract with 5 mg of antiphosphotyrosine antibodies (pY20, BD Transduction Laboratories; Lexington, KY, USA) for 2 h at 41C. Protein A-Sepharose beads were added for 2 additional h, followed by three extensive washes with Buffer A. SDSpolyacrylamide gel electrophoresis (PAGE) and blotting were performed as described (Gil-Henn et al., 2001) . c-Src kinase assay was performed as described previously (GilHenn and Elson, 2003) by precipitating c-Src from cell lysates and allowing it to phosphorylate enolase with g-32 P-ATP. In some cases, 100 mg of total cell protein was incubated with 10 units of calf intestinal alkaline phosphatase for 2 h at 41C.
Purification of RPTPe and phosphatase activity assay Beads carrying precipitated FLAG-tagged WT and Y695E RPTPe were washed once in Buffer A, three times in Buffer B (20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES, pH 7.6), 100 mM KCl, 0.5 mM ethylenediaminetetraacetic acid (EDTA), 0.4% NP-40 and 20% glycerol) and twice briefly in 54 K buffer (50 mM Tris (pH 8), 150 mM NaCl and 0.5% Triton X-100). Molecules were eluted in an equal volume of elution buffer (20 mM HEPES (pH 7.3), 200 mM NaCl, 1 mM EDTA, 0.1 mM ethylene glycol tetraacetic acid (EGTA)) containing 1 mg/ml FLAG peptide (Sigma) for 3 min at 301C. Phosphatase activity of 220 ng of eluted RPTPe was assayed in 96-well plates as described (Toledano-Katchalski et al., 2003) using increasing concentrations of paranitrophenylphosphate (PNPP, 0.6, 0.9, 1.5, 3, 6, 12 and 15 mM). Activity was measured by monitoring the increase in absorption at 405 nm during the first 5-15 min, during which absorption was linear with time. K m and V max were derived from LineweaverBurk analysis of the data. Negative controls containing eluted RPTPe and 0.5 mM sodium pervanadate exhibited negligible activity. Experiments were repeated three times.
